QR kód

From Monoclonal to Bispecific Antibodies, The Next Step of Immunotherapy for Non-Small Cell Lung Cancer

Abstract Lung cancer remains the leading cause of cancer-related deaths worldwide. Immune checkpoint inhibitors (ICIs) and bispecific antibodies (bsAbs) are transforming the treatment landscape, particularly in non-small cell lung cancer (NSCLC). Perioperative immunotherapy trials, such as RATIONALE...

Celý popis

Uloženo v:
Hlavní autoři: Yang Xia, Mo Zhou, Da Miao, Fei Zhou, Caicun Zhou
Médium: Artigo
Jazyk:Inglês
Vydáno: Springer 2025-11-01
Edice:Holistic Integrative Oncology
Témata:
NSCLC
Immunotherapy
Bispecific antibodies
Perioperative treatment
Ivonescimab
On-line přístup:https://doi.org/10.1007/s44178-025-00209-w
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Podobné jednotky